Aaron Quiggle, MD, MS
Adult, child, and adolescent addiction psychiatrist; Medical Director, Addiction Recovery Management Service (ARMS), Massachusetts General Hospital, Boston, MA.
Dr. Quiggle is a co-investigator of an investigator-sponsored trial for Ironshore Pharmaceuticals. Relevant financial relationships have been mitigated.
Earth Hasassri, MD. Dr. Hasassri has no financial relationships with companies related to this material.
Natalie Pon, MD
Child and adolescent psychiatrist, Children’s Health Council; adjunct clinical faculty, Stanford University, Palo Alto, CA.
Dr. Pon has no financial relationships with companies related to this material.
Alyssa Aikman, MSN, APRN, PMHNP-BC. Psychiatric nurse practitioner in outpatient group practice, Vancouver, WA.
Ms. Aikman has no financial relationships with companies related to this material.
Mark L. Ruffalo, MSW, DPsa. Editor in Chief, The Carlat Psychotherapy Report, psychotherapist in private practice in Tampa, Florida, and Assistant Professor of Psychiatry at the University of Central Florida College of Medicine and Adjunct Instructor of Psychiatry at Tufts University School of Medicine. He has broad clinical experience in the psychoanalytic treatment of mood, personality, and psychosomatic disorders, and has particular interest in the psychotherapy of schizophrenia and borderline personality disorder.
Dr. Ruffalo has no financial relationships with companies related to this material.
Aydar Shaildayev, MD. Psychiatry resident, NYU Langone, New York, NY.
Eric Whitney, MD. Clinical assistant professor, Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, NY.
Drs. Shaildayev and Whitney have no financial relationships with companies related to this material.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?t=1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
